S&P 500   4,368.58 (+0.97%)
DOW   34,291.53 (+0.38%)
QQQ   346.92 (+1.71%)
AAPL   168.22 (+5.65%)
MSFT   303.99 (+1.38%)
FB   299.12 (+1.52%)
GOOGL   2,633.48 (+2.07%)
AMZN   2,817.84 (+0.90%)
TSLA   848.00 (+2.28%)
NVDA   224.48 (+2.30%)
BABA   112.86 (+0.96%)
NIO   21.00 (-0.52%)
AMD   104.00 (+1.36%)
CGC   7.18 (+4.82%)
MU   78.00 (-0.91%)
GE   90.33 (+0.48%)
T   24.57 (+1.87%)
F   19.49 (-0.31%)
DIS   135.91 (+0.36%)
AMC   14.45 (-0.48%)
PFE   54.38 (+1.89%)
ACB   3.89 (+2.64%)
BA   187.96 (-0.94%)
S&P 500   4,368.58 (+0.97%)
DOW   34,291.53 (+0.38%)
QQQ   346.92 (+1.71%)
AAPL   168.22 (+5.65%)
MSFT   303.99 (+1.38%)
FB   299.12 (+1.52%)
GOOGL   2,633.48 (+2.07%)
AMZN   2,817.84 (+0.90%)
TSLA   848.00 (+2.28%)
NVDA   224.48 (+2.30%)
BABA   112.86 (+0.96%)
NIO   21.00 (-0.52%)
AMD   104.00 (+1.36%)
CGC   7.18 (+4.82%)
MU   78.00 (-0.91%)
GE   90.33 (+0.48%)
T   24.57 (+1.87%)
F   19.49 (-0.31%)
DIS   135.91 (+0.36%)
AMC   14.45 (-0.48%)
PFE   54.38 (+1.89%)
ACB   3.89 (+2.64%)
BA   187.96 (-0.94%)
S&P 500   4,368.58 (+0.97%)
DOW   34,291.53 (+0.38%)
QQQ   346.92 (+1.71%)
AAPL   168.22 (+5.65%)
MSFT   303.99 (+1.38%)
FB   299.12 (+1.52%)
GOOGL   2,633.48 (+2.07%)
AMZN   2,817.84 (+0.90%)
TSLA   848.00 (+2.28%)
NVDA   224.48 (+2.30%)
BABA   112.86 (+0.96%)
NIO   21.00 (-0.52%)
AMD   104.00 (+1.36%)
CGC   7.18 (+4.82%)
MU   78.00 (-0.91%)
GE   90.33 (+0.48%)
T   24.57 (+1.87%)
F   19.49 (-0.31%)
DIS   135.91 (+0.36%)
AMC   14.45 (-0.48%)
PFE   54.38 (+1.89%)
ACB   3.89 (+2.64%)
BA   187.96 (-0.94%)
S&P 500   4,368.58 (+0.97%)
DOW   34,291.53 (+0.38%)
QQQ   346.92 (+1.71%)
AAPL   168.22 (+5.65%)
MSFT   303.99 (+1.38%)
FB   299.12 (+1.52%)
GOOGL   2,633.48 (+2.07%)
AMZN   2,817.84 (+0.90%)
TSLA   848.00 (+2.28%)
NVDA   224.48 (+2.30%)
BABA   112.86 (+0.96%)
NIO   21.00 (-0.52%)
AMD   104.00 (+1.36%)
CGC   7.18 (+4.82%)
MU   78.00 (-0.91%)
GE   90.33 (+0.48%)
T   24.57 (+1.87%)
F   19.49 (-0.31%)
DIS   135.91 (+0.36%)
AMC   14.45 (-0.48%)
PFE   54.38 (+1.89%)
ACB   3.89 (+2.64%)
BA   187.96 (-0.94%)
NASDAQ:TELA

TELA Bio Stock Forecast, Price & News

$11.35
0.00 (0.00%)
(As of 01/28/2022 10:59 AM ET)
Add
Compare
Today's Range
$11.15
$11.35
50-Day Range
$11.35
$13.70
52-Week Range
$11.03
$18.00
Volume
102 shs
Average Volume
44,846 shs
Market Capitalization
$164.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.66
30 days | 90 days | 365 days | Advanced Chart
Receive TELA News and Ratings via Email

Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter.


TELA Bio logo

About TELA Bio

TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Headlines

Comparing TELA Bio (NASDAQ:TELA) and Vapotherm (NYSE:VAPO)
January 23, 2022 |  americanbankingnews.com
TELA Bio, Inc. Common Stock (TELA)
January 12, 2022 |  nasdaq.com
TELA Bio, Inc. (TELA) Q3 2021 Earnings Call Transcript
November 11, 2021 |  finance.yahoo.com
TELA Bio to Participate in Three Upcoming Conferences
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TELA
Phone
N/A
Fax
N/A
Employees
108
Year Founded
N/A

Sales & Book Value

Annual Sales
$18.21 million
Book Value
$3.40 per share

Profitability

Net Income
$-28.79 million
Net Margins
-121.27%
Pretax Margin
-121.27%

Debt

Price-To-Earnings

Miscellaneous

Free Float
12,198,000
Market Cap
$164.62 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/28/2022
Next Earnings (Estimated)
3/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

744th out of 1,417 stocks

Surgical & Medical Instruments Industry

78th out of 130 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -












TELA Bio (NASDAQ:TELA) Frequently Asked Questions

How has TELA Bio's stock been impacted by COVID-19 (Coronavirus)?

TELA Bio's stock was trading at $11.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TELA stock has decreased by 4.6% and is now trading at $11.35.
View which stocks have been most impacted by COVID-19
.

When is TELA Bio's next earnings date?

TELA Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for TELA Bio
.

How were TELA Bio's earnings last quarter?

TELA Bio, Inc. (NASDAQ:TELA) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.05. The firm earned $7.65 million during the quarter, compared to the consensus estimate of $7.30 million. TELA Bio had a negative trailing twelve-month return on equity of 84.60% and a negative net margin of 121.27%.
View TELA Bio's earnings history
.

What guidance has TELA Bio issued on next quarter's earnings?

TELA Bio updated its FY 2021 earnings guidance on Wednesday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28 million-$30 million, compared to the consensus revenue estimate of $29.46 million.

Who are TELA Bio's key executives?

TELA Bio's management team includes the following people:
  • Mr. Antony Koblish, Co-founder, Pres, CEO & Director (Age 55, Pay $806.25k)
  • Dr. E. Skott Greenhalgh Ph.D., Chief Technology Officer (Age 53, Pay $488.63k)
  • Mr. Paul Talmo, Chief of Strategy
  • Mr. Peter C. Murphy, Chief Commercial Officer (Age 48)
  • Mr. Francis Michael Conway, VP of Fin., Treasurer & Assistant Sec.
  • Mr. David C. Toner Esq., J.D., Sec.
  • Ms. Megan Smeykal, VP & Corp. Controller

What other stocks do shareholders of TELA Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TELA Bio investors own include Micron Technology (MU), Intel (INTC), Pfizer (PFE), CrowdStrike (CRWD), Walt Disney (DIS), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Alteryx (AYX) and Cisco Systems (CSCO).

When did TELA Bio IPO?

(TELA) raised $60 million in an initial public offering on Friday, November 8th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is TELA Bio's stock symbol?

TELA Bio trades on the NASDAQ under the ticker symbol "TELA."

How do I buy shares of TELA Bio?

Shares of TELA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TELA Bio's stock price today?

One share of TELA stock can currently be purchased for approximately $11.35.

How much money does TELA Bio make?

TELA Bio has a market capitalization of $164.62 million and generates $18.21 million in revenue each year. The company earns $-28.79 million in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does TELA Bio have?

TELA Bio employs 108 workers across the globe.

What is TELA Bio's official website?

The official website for TELA Bio is www.telabio.com.

Where are TELA Bio's headquarters?

How can I contact TELA Bio?

TELA Bio's mailing address is 1 GREAT VALLEY PARKWAY SUITE 24, MALVERN PA, 19355. The company can be reached via email at [email protected].


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.